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Abstract
Background: Oxaliplatin is a platinum derivative that has shown efficacy in advanced hepatocellular carcinoma. S-1
is an oral fluoropyrimidine that has substituted for 5-fluorouracil in many cancers. This was a multicenter, open-
label, single-arm phase II trial that evaluated the efficacy of S-1 and oxaliplatin (SOX) in advanced hepatocellular
carcinoma. All patients included in the present study were systemic treatment-naïve. Prior treatment with sorafenib
was allowed, but other treatments were not.
Methods: Patients received S-1 (40 mg/m2 twice daily from day 1–14) and oxaliplatin (130 mg/m2 on day 1) every
3 weeks. The primary end point was time to progression (TTP). Secondary end points included progression-free
survival, overall survival (OS), response rate, and safety profile.
Results: Thirty six patients with advanced hepatocellular carcinoma were included in this study. The median TTP was 3.
0 months (95% confidence interval (CI), 0.75–5.25), and the median OS was 10.3 months (95% CI, 6.4–14.3). Bone
metastasis was associated with poorer TTP and OS. The efficacy of SOX was unaffected by prior sorafenib or locoregional
therapy. The objective response rate was 13.9%. No grade 4 toxicity or death from adverse events occurred. The most
common grade 3 toxicities were neutropenia (13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%).
Conclusions: Although this trial did not meet its primary end point, the SOX regimen showed comparable efficacy and
safety to the 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen. As the SOX regimen is easier for patients, SOX
may be a reasonable substitute for FOLFOX in hepatocellular carcinoma.
Trial registration: Clinicaltrials.gov NCT01429961. Registered 7 September 2011.
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Background
Liver cancer is the second and sixth most frequent cause
of death from cancer in men and women, respectively [1].
Overall, 70% to 90% of liver cancers are hepatocellular car-
cinoma, which has poorer prognosis, as most patients are
diagnosed at advanced stages and have underlying hepatic
dysfunction [2]. Sorafenib, a multi-tyrosine kinase inhibi-
tor, has shown efficacy in advanced hepatocellular
carcinoma and is the only molecular targeted agent ap-
proved for hepatocellular carcinoma based on two phase
III trials [3, 4].
Hepatocellular carcinoma is highly refractory to conven-
tional systemic chemotherapy [5]. Although doxorubicin
is a palliative treatment in hepatocellular carcinoma, no
studies have found strong evidence for the survival benefit
of doxorubicin. However, in a phase III clinical trial per-
formed in Asia (EACH trial) which compared the efficacy
of FOLFOX (5-fluorouracil (5-FU), leucovorin, and oxali-
platin) and doxorubicin, FOLFOX showed prolonged pro-
gression free survival (PFS, 2.93 months vs. 1.77 months)
and overall survival (OS, 6.40 months vs. 4.97 months)
compared to doxorubicin [6]. In a study performed in a
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Western population, gemcitabine combined with oxalipla-
tin showed efficacy (median PFS and OS of 4.5 and
11.0 months, respectively) in a multicenter retrospective
study [7]. Although conventional chemotherapy has never
been compared directly with sorafenib, these findings
show that conventional chemotherapy may be an option
for advanced hepatocellular carcinoma patients.
S-1 is an oral fluoropyrimidine agent, consisting of
tegafur (a pro-drug of 5-FU), gimeracil, and oteracil.
Gimeracil and oteracil decrease 5-FU anti-metabolite
degradation and achieve higher concentrations of 5-FU
in the plasma and tumor tissues. Recently, 5-FU has
been substituted by oral fluoropyrimidines, such as cape-
citabine or S-1, to treat many cancers based on phase III
study results showing comparable efficacy and better
safety profiles with oral fluoropyrimidines [8–12]. There-
fore, we performed a phase II study to evaluate the effi-
cacy and safety of S-1 and oxaliplatin (SOX) in patients
with advanced hepatocellular carcinoma.
Methods
Study design and participants
This study was a multicenter, open-label, single-arm,
phase 2 trial that evaluated the efficacy of SOX in ad-
vanced hepatocellular carcinoma. Patients with hepatocel-
lular carcinoma of Barcelona Clinic Liver Cancer stage C
that was either refractory or not amenable to locoregional
therapy were eligible for the present study. Hepatocellular
carcinoma was diagnosed based on 2005 AASLD practice
guidelines [13]. Either histopathological findings from
tumor tissue or non-histological diagnosis based on
triphasic CT scan and/or gadolinium enhanced MRI was
required [13]. Without histological confirmation, liver
mass ≥ 2 cm with characteristic vascularization (either on
a triphasic CT scan or gadolinium-enhanced MRI) or
AFP ≥ 200 μg/L was required. In patients with a 1 to 2 cm
liver mass, characteristic vascularization on both a tripha-
sic CT scan and gadolinium-enhanced MRI were required
with concomitant liver cirrhosis. At least one measurable
extrahepatic lesion based on the Response Evaluation Cri-
teria in Solid Tumors (RECIST) criteria 1.1 was required.
Other main inclusion criteria were an age of over 18 years;
Eastern Cooperative Oncology Group performance status
(ECOG PS) of 0 to 2; Child-Pugh class A; adequate bone
marrow, hepatic, and renal function [absolute neutrophil
count (ANC) ≥ 1500/μL; platelet count ≥100,000/μL, total
bilirubin ≤2 X upper limit of normal (ULN); serum trans-
aminases ≤2.5 X ULN; alkaline phosphatase ≤2.5 X ULN;
serum creatinine ≤1.5 X ULN]. Patients with serum trans-
aminases and alkaline phosphatase ≤5 X ULN could be in-
cluded if they had a normal total bilirubin level. Patients
were excluded if they had either previous systemic chemo-
therapy (except prior sorafenib) or history of another ma-
lignancy within the last 5 years.
The study protocol was reviewed and approved by the in-
stitutional review board of Seoul National University Hos-
pital, Seoul, Korea [H-1010-054-336]. This study was
conducted in accordance with the recommendations of the
Declaration of Helsinki for biomedical research involving
human subjects and the Guidelines for Good Clinical Prac-
tice (ClinicalTrial.gov Identifier: NCT01429961). Written
informed consent was obtained from each patient before
enrollment.
Treatment and dose modification
S-1 was administered orally at a dose of 40 mg/m2 twice
daily for 14 days (80 mg/m2/day), followed by a 7-day
rest period. Oxaliplatin was given as a 120–minute infu-
sion on day 1 of each cycle at a dose of 130 mg/m2.
Dose reduction of S-1 (30 mg/m2 twice daily, which is
60 mg/m2/day) and Oxaliplatin (100 mg/m2) was
allowed per the discretion of the treating physician, as
most patients with HCC have compensated liver cirrho-
sis despite a Child-Pugh class A score. Treatment was
repeated every 3 weeks until disease progression, un-
acceptable toxicity, or withdrawal of patient consent.
Drug administration was delayed until an ANC of
≥1500/μL and platelet counts of ≥100,000/μL, and re-
covery from non-hematological toxicity to baseline or
less than or equal to grade 1. S-1 was reduced to a dose
of 30 mg/m2 twice daily (60 mg/m2/day) and oxaliplatin
was reduced to a dose of 100 mg/m2 on all subsequent
cycles for febrile neutropenia, grade 4 neutropenia, grade
3/4 thrombocytopenia, or greater than or equal to grade
3 non-hematological toxic effects.
Assessment
Baseline assessments included medical history, physical
examination, electrocardiography, chest X-rays, abdom-
inal and pelvic CT scans (gadolinium enhanced MRI
when necessary), complete blood counts, serum electro-
lytes and chemistry, and urine analysis. Tumor response
was assessed using RECIST criteria 1.1, with contrast-
enhanced triphasic CT scans at baseline and every two
cycles (6 weeks). Toxicity was evaluated at each cycle
per the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.0.
Statistical analysis
The primary end point of this study was time to pro-
gression (TTP), which was defined as the time from
study enrollment to tumor progression. Deaths without
progressive disease were censored in the TTP analysis.
Secondary end points were OS, PFS, response rate, and
toxicity. OS was calculated from the date of study enroll-
ment to the date of death. PFS was defined as the inter-
val between the date of study enrollment and first date
of documented progressive disease or the date of death
Lee et al. BMC Cancer  (2018) 18:252 Page 2 of 7
from any cause. Tumor response was assessed using
RECIST criteria 1.1. TTP, PFS, and OS were estimated
using the Kaplan-Meier method and comparisons were
made using log-rank tests. Statistical analysis was per-
formed using SPSS software for Windows, version 18.0
(SPSS, Chicago, IL, USA).
We hypothesized an increased TTP from 2.8 months
to 4.0 months in the SOX group. With an alpha of 0.10
and a power of 80%, 34 patients were required for this
study. Considering a 10% loss to follow-up rate, the tar-
get enrollment was 38 patients.
Results
Patient characteristics
Between May 27, 2011, and August 28, 2014, 36 patients
were enrolled. All patients included in our cohort met the
diagnostic criteria for both 2005 and 2010 AASLD guide-
lines [14]. Baseline characteristics of the patients are sum-
marized in Table 1. The median patient age was 58 years
(range, 21–74), and 33 patients (91.7%) were male. All pa-
tients had at least 1 extrahepatic measurable lesion and
good ECOG PS. Per the inclusion criteria, all patients
were classified as Child-Pugh class A and had adequate
hepatic function. On the baseline CT/MRI, 94.4% (34/36)
showed liver cirrhosis. Of the 36 patients, 31 patients were
treated with prior sorafenib or locoregional therapy
(TACE, PEIT, or RFA). One patient did not receive either
prior sorafenib or locoregional therapy.
Efficacy
Response evaluation was available for all 36 patients.
One patient achieved a complete response (CR, 2.8%), 4
had a partial response (PR, 11.1%), 13 had stable disease
(SD, 36.1%), and 18 had progressive disease (PD, 50.0%).
The overall response rate (ORR) was 13.9% and the dis-
ease control rate (DCR) was 50.0%.
With a median follow-up of 10.9 months, 35 progres-
sion events and 34 deaths occurred. PFS and TTP were
the same in our cohort as no patients died without pro-
gression. The median TTP and PFS were 3.0 months
(95% confidence interval (CI), 0.7–5.3) (Fig. 1), and the
median OS was 10.3 months (95% CI, 6.4–14.3) (Fig. 2).
The trial did not meet its primary end point of a 4-
month TTP. Bone metastasis was associated with poorer
survival (hazard ratio (HR) for TTP 2.31, 95% CI 1.02–
5.21, p = 0.045) (HR for OS 2.36, 95% CI 1.05–5.30, p =
0.037) (Fig. 3). Gender, age, PS, AFP level, PIVKA level,
prior sorafenib treatment, prior locoregional therapy,
and lung or liver metastasis were unassociated with TTP
and OS. In patients treated with prior sorafenib (31/36,
86.6%), median TTP and OS were 3.0 (95% CI, 1.2–4.8)
months and 9.5 (95% CI, 5.4–13.7) months, respectively.
Toxicity
Patients received a total of 199 treatment cycles, with a
median of 3 cycles (range, 1–27) per patient. Study treat-
ments were discontinued in 2 patients (5.5%) because of
severe adverse events, including spontaneous bacterial
peritonitis and hepatocellular carcinoma rupture. Nine pa-
tients (25.0%) started chemotherapy at a reduced dose and
27 (75.0%) started chemotherapy at the regular dose. Of
the 27 patients who started chemotherapy at the regular
dose, 11 (40.7%) had their dose reduced during the
chemotherapy cycle due to toxicity. This includes four
cases of grade 3 thrombocytopenia, three cases of grade 3





Median (range) 58 (21–74)





Hepatitis B 26 (72.2%)
Hepatitis C 1 (2.8%)













Locoregional therapya 31 (86.1%)
AFP
< 200 ng/mL 22 (61.1%)
≥ 200 ng/mL 14 (38.9%)
PIVKA
< 400 mAU/mL 17 (47.2%)
≥ 400 mAU/mL 19 (52.8%)
Abbreviations: ECOG, Eastern Cooperative Oncology Group, PS
performance status
aincludes transcatheter arterial chemoembolization (TACE), percutaneous
ethanol injection therapy (PEIT), and radiofrequency ablation (RFA)
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diarrhea, one case of grade 3 neutropenia, one case of
grade 3 sensory neuropathy, one case of grade 2 gastro-
intestinal bleeding, and one case of septic shock due to
pneumonia. All 11 patients recovered from the adverse
event and received subsequent chemotherapy at a reduced
dose. No treatment-related death or grade 4 toxicity oc-
curred during the study. Detailed toxic events per patient
are shown in Table 2. The most common adverse event of
any grade was sensory neuropathy (52.8%), followed by
thrombocytopenia (41.7%), diarrhea (38.9%), nausea
(36.1%), anorexia (33.3%), and neutropenia (30.1%). The
most common grade 3 toxicities were neutropenia
(13.9%), thrombocytopenia (13.9%), and diarrhea (8.3%).
Discussion
The results of our phase 2 study show that the SOX
regimen may be an option for managing patients with
advanced hepatocellular carcinoma. The median TTP/
PFS was 3.0 months (95% CI, 0.7–5.3), median OS was
10.3 months (95% CI, 6.4–14.3), ORR was 13.9%, and
DCR was 50.0%. Although the study did not meet its
primary end point (TTP of 4.0 months), SOX showed
comparable efficacy with FOLFOX in the EACH trial
(PFS: 2.93 months, OS: 6.40 months, ORR: 8.15%, DCR:
52.17%) [6].
In this study, no grade 4 toxicity resulted from the
SOX regimen. Most adverse events were grade 1/2 and
common grade 3 toxicities were neutropenia and
thrombocytopenia. However, most patients with grade 3
toxicity were easily managed and tolerated after a dose
reduction. Although 2 patients stopped chemotherapy
due to severe adverse events, these events (spontaneous
bacterial peritonitis and hepatocellular carcinoma rup-
ture) were not directly associated with chemotherapy
toxicity. Although we cannot directly compare our re-
sults to the EACH trial, the SOX regimen showed a
better safety profile than the FOLFOX regimen [6].
Fifty-five percent of patients treated with FOLFOX had
an adverse event over grade 3, and 6% died from the se-
vere adverse event. In addition, 23% of patients discon-
tinued FOLFOX chemotherapy due to adverse events.
Sorafenib is the current standard of care in managing
advanced hepatocellular carcinoma. Several studies
have investigated the efficacy of novel molecular-
targeted agents (sunitinib, everolimus, brivanib, linifa-
nib, and ramucirumab) in first-line or second-line set-
tings [15–20]. However, all studies were negative except
for regorafenib which showed efficacy in sorafenib-
resistant hepatocellular carcinoma [21]. Currently, few
options exist to manage patients with advanced hepato-
cellular carcinoma. In addition, sorafenib efficacy is
modest in Asian patients compared to Western patients
[3, 4]. Although FOLFOX has not been compared dir-
ectly with sorafenib, previous results support FOLFOX
as a reasonable option for managing advanced hepato-
cellular carcinoma. In this study we evaluated the effi-
cacy of SOX in advanced hepatocellular carcinoma. S-1
is an oral fluoropyrimidine which can substitute 5-FU
in many cancers. Our results show that SOX is compar-
able to FOLFOX and may be an alternative to FOL-
FOX. Moreover, TTP and OS were unaffected by
whether the patients received prior sorafenib or locore-
gional therapy. In a single center retrospective study,
the SOX regimen showed efficacy comparable to that of
sorafenib in advanced hepatocellular carcinoma [22].
Thus, the SOX regimen may be an effective option in
pre-treated or treatment-naïve advanced hepatocellular
carcinoma patients.
Fig. 1 Kaplan–Meier survival curve for time to progression
Fig. 2 Kaplan–Meier survival curve for overall survival
Lee et al. BMC Cancer  (2018) 18:252 Page 4 of 7
In this study, bone metastasis was associated with
poorer survival in patients treated with the SOX regi-
men. As this study was a single-arm study, we cannot
determine whether this poorer survival was due to its
innate aggressive biology of the metastasis or its resist-
ance to chemotherapy. Although bone is a frequent ex-
trahepatic metastatic site, its prognostic role is
unknown [23]. Evidence shows that hepatocellular car-
cinoma patients with bone metastasis may derive sur-
vival benefit from locoregional and/or systemic
chemotherapy compared to the best supportive care
(OS, 9.7 vs. 2.9 months, log-rank test p = 0.081) [24].
Prognostic and predictive roles of bone metastasis in
patients with hepatocellular carcinoma should be
assessed in larger studies.
Conclusion
This phase II study indicates that combination therapy
with S-1 and oxaliplatin may be effective in patients with
advanced hepatocellular carcinoma. Toxicity was moder-
ate, but manageable. Patients with bone metastasis
showed poorer survival following SOX treatment. As the
SOX regimen shows comparable efficacy with FOLFOX
and is easier for patients, SOX may be a reasonable sub-
stitute for FOLFOX in patients with advanced hepatocel-
lular carcinoma.
Fig. 3 Kaplan–Meier curves of TTP and OS according to the presence of bone metastasis. Abbreviations: TTP, time to progression; OS,
overall survival
Table 2 Toxicity profile
All courses (total N = 36)
Grade 1 Grade 2 Grade 3 Total
Neutropeniaa N/A 6 (16.7%) 5 (13.9%) 11 (30.1%)
Thrombocytopeniaa N/A 10 (27.8%) 5 (13.9%) 15 (41.7%)
Bilirubina N/A 2 (5.6%) 0 (0.0%) 2 (5.6%)
AST/ALTa N/A 1 (2.8%) 1 (2.8%) 2 (5.6%)
Asthenia 4 (11.1%) 3 (8.3%) 1 (2.8%) 8 (22.2%)
Anorexia 10 (27.8%) 2 (5.6%) 0 (0.0%) 12 (33.3%)
Nausea 13 (36.1%) 0 (0.0%) 0 (0.0%) 13 (36.1%)
Vomit 5 (13.9%) 0 (0.0%) 0 (0.0%) 5 (13.9%)
Abdominal pain 7 (19.4%) 1 (2.8%) 0 (0.0%) 8 (22.2%)
Stomatitis 8 (22.2%) 1 (2.8%) 0 (0.0%) 9 (25%)
Diarrhea 8 (22.2%) 3 (8.3%) 3 (8.3%) 14 (38.9%)
Constipation 5 (13.9%) 2 (5.6%) 0 (0.0%) 7 (19.4%)
Sensory neuropathy 14 (38.9%) 4 (11.1%) 1 (2.8%) 19 (52.8%)
Motor neuropathy 0 (0.0%) 1 (2.8%) 0 (0.0%) 1 (2.8%)
Skin rash 2 (5.6%) 1 (2.8%) 0 (0.0%) 3 (8.3%)
Abbreviations: AST Aspartate aminotransferase, ALT Alanine aminotransferase, N/A not assessed
aToxicities with Grade 2 or more were counted for these items
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Abbreviations
5-FU: 5-fluorouracil; ANC: Absolute neutrophil count; CI: Confidence interval;
CR: Complete response; DCR: Disease control rate; ECOG PS: Eastern
Cooperative Oncology Group performance status; FOLFOX: 5-fluorouracil,
leucovorin, and oxaliplatin; HR: Hazard ratio; ORR: Overall response rate;
OS: Overall survival; PD: Progressive disease; PFS: Progression free survival;
PR: Partial response; RECIST: Response Evaluation Criteria in Solid Tumors;
SD: Stable disease; SOX: S-1 and oxaliplatin; TTP: Time to progression;
ULN: Upper limit of normal
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